JP2023513704A5 - - Google Patents
Info
- Publication number
- JP2023513704A5 JP2023513704A5 JP2022548599A JP2022548599A JP2023513704A5 JP 2023513704 A5 JP2023513704 A5 JP 2023513704A5 JP 2022548599 A JP2022548599 A JP 2022548599A JP 2022548599 A JP2022548599 A JP 2022548599A JP 2023513704 A5 JP2023513704 A5 JP 2023513704A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- erdafitinib
- patient
- fgfr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026034354A JP2026097934A (ja) | 2020-02-12 | 2026-03-04 | 高リスク筋層非浸潤性膀胱癌を治療するためのfgfrチロシンキナーゼ阻害剤 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062975547P | 2020-02-12 | 2020-02-12 | |
| US62/975,547 | 2020-02-12 | ||
| US202063018914P | 2020-05-01 | 2020-05-01 | |
| US63/018,914 | 2020-05-01 | ||
| US202063118475P | 2020-11-25 | 2020-11-25 | |
| US63/118,475 | 2020-11-25 | ||
| PCT/EP2021/053385 WO2021160764A1 (en) | 2020-02-12 | 2021-02-11 | Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026034354A Division JP2026097934A (ja) | 2020-02-12 | 2026-03-04 | 高リスク筋層非浸潤性膀胱癌を治療するためのfgfrチロシンキナーゼ阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023513704A JP2023513704A (ja) | 2023-04-03 |
| JP2023513704A5 true JP2023513704A5 (cg-RX-API-DMAC7.html) | 2024-02-21 |
Family
ID=74666675
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548599A Withdrawn JP2023513704A (ja) | 2020-02-12 | 2021-02-11 | 高リスク筋層非浸潤性膀胱癌を治療するためのfgfrチロシンキナーゼ阻害剤 |
| JP2026034354A Pending JP2026097934A (ja) | 2020-02-12 | 2026-03-04 | 高リスク筋層非浸潤性膀胱癌を治療するためのfgfrチロシンキナーゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026034354A Pending JP2026097934A (ja) | 2020-02-12 | 2026-03-04 | 高リスク筋層非浸潤性膀胱癌を治療するためのfgfrチロシンキナーゼ阻害剤 |
Country Status (14)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312063A (en) * | 2021-10-12 | 2024-06-01 | Taris Biomedical Llc | Ardafitinib formulations and systems for intravesical administration |
| JP2025506402A (ja) * | 2022-02-04 | 2025-03-11 | ヤンセン ファーマシューティカ エヌ.ベー. | 転移性去勢抵抗性前立腺癌及びhrr変化を有する患者における臨床アウトカムを改善するためのニラパリブ及び酢酸アビラテロン+プレドニゾン |
| WO2023159216A1 (en) * | 2022-02-18 | 2023-08-24 | Taris Biomedical Llc | Erdafitinib formulations and osmotic systems for intravesical administration |
| IL322667A (en) * | 2023-02-13 | 2025-10-01 | Taris Biomedical Llc | Ardepitinib for intravesical administration for use in the treatment of bladder cancer |
| KR20250148646A (ko) * | 2023-02-13 | 2025-10-14 | 얀센 파마슈티카 엔브이 | 고위험 비근침윤성 방광암 치료를 위한 fgfr 티로신 키나제 억제제 |
| CN120731077A (zh) * | 2023-02-17 | 2025-09-30 | 塔里斯生物医药公司 | 膀胱内施用厄达替尼以用于治疗膀胱癌 |
| CN121891539A (zh) * | 2026-02-06 | 2026-04-21 | 深圳大学 | 一种靶向iCAFs亚群的FGF2抑制剂组合物及其在膀胱癌防治中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| CA2744096C (en) | 1996-07-31 | 2013-07-30 | Laboratory Corporation Of America Holdings | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| EP2270000B1 (en) | 2005-05-23 | 2015-07-29 | Novartis AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| SG11201702381QA (en) * | 2014-09-26 | 2017-04-27 | Janssen Pharmaceutica Nv | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
| TWI719960B (zh) * | 2015-02-10 | 2021-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| CA3049737A1 (en) * | 2017-02-06 | 2018-08-09 | Janssen Pharmaceutica Nv | Cancer treatment |
| MA47408B1 (fr) * | 2017-12-20 | 2023-08-31 | Janssen Pharmaceutica Nv | Traitement du cancer |
-
2021
- 2021-02-11 PH PH1/2022/552093A patent/PH12022552093A1/en unknown
- 2021-02-11 MX MX2022009905A patent/MX2022009905A/es unknown
- 2021-02-11 EP EP21706187.8A patent/EP4103185A1/en active Pending
- 2021-02-11 CN CN202180014162.9A patent/CN115103678A/zh active Pending
- 2021-02-11 AU AU2021220285A patent/AU2021220285A1/en active Pending
- 2021-02-11 CA CA3162962A patent/CA3162962A1/en active Pending
- 2021-02-11 BR BR112022015827A patent/BR112022015827A2/pt unknown
- 2021-02-11 KR KR1020227031209A patent/KR20220140781A/ko active Pending
- 2021-02-11 JP JP2022548599A patent/JP2023513704A/ja not_active Withdrawn
- 2021-02-11 IL IL295514A patent/IL295514A/en unknown
- 2021-02-11 US US17/904,139 patent/US20230110113A1/en active Pending
- 2021-02-11 WO PCT/EP2021/053385 patent/WO2021160764A1/en not_active Ceased
- 2021-02-17 TW TW110105372A patent/TW202143970A/zh unknown
-
2022
- 2022-08-09 JO JOP/2022/0182A patent/JOP20220182A1/ar unknown
-
2026
- 2026-03-04 JP JP2026034354A patent/JP2026097934A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stadler et al. | A phase II study of depsipeptide in refractory metastatic renal cell cancer | |
| Goldberg et al. | Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. | |
| US9486445B2 (en) | Combination therapy for proliferative disorders | |
| AU2016244279B2 (en) | Method of adjuvant cancer treatment | |
| EA037152B1 (ru) | Способ лечения рака | |
| WO2017201156A1 (en) | Method of treating kras wild-type metastatic colorectal cell carcinoma using cabozantinib plus panitumumab | |
| JP2006501147A5 (cg-RX-API-DMAC7.html) | ||
| AU2018234903B2 (en) | Combination therapies for the treatment of breast cancer | |
| JP2025156297A (ja) | 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤 | |
| EP1750713B1 (en) | Use of imatinib to treat liver disorders and viral infections | |
| JP2022534118A5 (cg-RX-API-DMAC7.html) | ||
| HUP0204139A2 (en) | Use of n-[6-methoxi-5-(2-methoxiphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]-2phenyl-etienesulfonamide for producing pharmaceutical composition using for reducing pain in an endothelin-induced disease | |
| TW202034921A (zh) | 癌症療法 | |
| WO2007083119A2 (en) | Methods | |
| CN113260363A (zh) | 格拉普兰特(grapiprant)单位剂型 | |
| KR20230043598A (ko) | 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염 및 항바이러스제를 유효성분으로 함유하는 코로나바이러스감염증-19(covid-19) 치료용 조성물 | |
| TW200412971A (en) | Therapeutic treatment | |
| KR101741281B1 (ko) | 건선 치료를 위한 a3 아데노신 수용체 작동약 (ib-meca/cf-101)을 포함하는 제약학적 조성물 | |
| WO2020248240A1 (zh) | 痘苗病毒致炎兔皮提取物治疗癌症的用途 | |
| TW202300145A (zh) | 藥物組合、包含其的試劑盒及其用途 | |
| CN120752038A (zh) | 瑞普替尼治疗胃肠道基质瘤的方法 | |
| CN112004525A (zh) | 注射用组合物 | |
| George et al. | 4517 POSTER Sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC) | |
| CN116847842A (zh) | Irak4降解剂和其用途 | |
| KR20230027226A (ko) | 화학요법-유발 설사를 치료하기 위한 방법 및 조성물 |